Cocrystal Pharma shareholders authorize capital reduction, elect directors, reject officer liability amendment

Cocrystal Pharma, Inc.

Shareholders approved reducing authorized capital to 100M common + 1M preferred shares; amendment effective June 27, 2024.
Six directors elected: Roger Kornberg, Phillip Frost, Fred Hassan, Anthony Japour, Richard Pfenniger, Steven Rubin.
Weinberg & Company ratified as independent auditor for fiscal year ending December 31, 2024.
Proposal to limit officer liability failed (4.85M for, 338K against; abstentions 26,484).
Non-binding advisory vote on exec compensation approved; company will hold say-on-pay vote every three years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.